TrialAmerican journal of hematology2010

Long-term results of single-agent thalidomide as initial therapy for asymptomatic (smoldering or indolent) myeloma.

Kristen Detweiler-Short et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.